🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

283 results for “ANI” Clear

  1. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  2. Peptides (N,R&C) formulated in Montanide ISA 720

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 small molecule completed

    1 trial

  3. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  4. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  5. Pretomanid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  6. RT-102 (80 μg)

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 other completed

    1 trial

  7. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani Therapeutics Holdings

    Obesity

    phase 1 other active

    1 trial

  8. RaniPill capsule containing octreotide

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 other completed

    1 trial

  9. Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

    Shanghai University of Traditional Chinese Medicine

    Healthy

    phase 1 small molecule completed

    1 trial

  10. Repetitive Transcranial Magnetic Stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 other terminated

    1 trial

  11. Sapanisertib

    Takeda

    Non-hematologic Malignancy

    phase 1 small molecule completed

    1 trial

  12. Stelara

    Rani Therapeutics Holdings

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. Sublingual Tizanidine HCl

    Teva Pharma GmbH

    Traumatic Brain Injury

    phase 1 small molecule completed

    1 trial

  14. TAK-935

    Takeda

    Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

    phase 1 small molecule completed

    1 trial

  15. Tranilast

    The First People's Hospital of Lianyungang

    Mucinoses

    phase 1 small molecule active

    1 trial

  16. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  17. ZW25 (Zanidatamab)

    Jazz Pharmaceuticals Ireland Limited

    HER2-expressing Cancers

    phase 1 small molecule completed

    1 trial

  18. [14C]-Danicopan

    Alexion Europe SAS

    Healthy

    phase 1 small molecule completed

    1 trial

  19. amoxicillin-clavulanic acid

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  20. α-lactalbumin vaccine

    Anixa Biosciences Inc

    Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer

    phase 1 mab active

    1 trial

  21. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  22. Brucea javanica oil emulsion injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    approved other active

    1 trial

  23. CEFEPIME, TEICOPLANIN, METRONIDAZOLE, METRONIDAZOLE, MEROPENEM, TAZOBACTAM, VANCOMYCIN, LEVOFLOXACIN, CIPROFLOXACIN, CEFTAZIDIME, METRONIDAZOLE, CIPROFLOXACIN, LEVOFLOXACIN, AMIKACIN, CIPROFLOXACIN, PIPERACILLIN

    The George Institute

    Infectious diseases

    approved small molecule active

    1 trial

  24. Chinese Herb Huang-Chi-Wu-Wu-Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracranial Arterial Stenosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources